Market closed

Biogen/$BIIB

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Ticker

$BIIB

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

7,570

Website

www.biogen.com

Biogen Metrics

BasicAdvanced

$21B

Market cap

13.24

P/E ratio

$11.06

EPS

-0.06

Beta

-

Dividend rate

Price and volume

Market cap

$21B

Beta

-0.06

52-week high

$268.30

52-week low

$145.07

Average daily volume

1.7M

Financial strength

Current ratio

1.259

Quick ratio

0.68

Long term debt to equity

29.97

Total debt to equity

40.656

Interest coverage (TTM)

5.16%

Management effectiveness

Return on assets (TTM)

4.99%

Return on equity (TTM)

10.47%

Valuation

Price to earnings (TTM)

13.241

Price to revenue (TTM)

2.215

Price to book

1.3

Price to tangible book (TTM)

315.69

Price to free cash flow (TTM)

12.035

Growth

Revenue change (TTM)

-3.86%

Earnings per share change (TTM)

10.05%

3-year revenue growth (CAGR)

-4.70%

3-year earnings per share growth (CAGR)

2.68%

What the Analysts think about Biogen

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Biogen stock.

Biogen Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Biogen Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Biogen News

AllArticlesVideos

Private Medicare plans must cover Biogen's ALS drug, US agency says

Reuters·2 weeks ago

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Benzinga·2 weeks ago

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Seeking Alpha·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIIB

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Biogen stock?

Biogen (BIIB) has a market cap of $21B as of December 24, 2024.

What is the P/E ratio for Biogen stock?

The price to earnings (P/E) ratio for Biogen (BIIB) stock is 13.24 as of December 24, 2024.

Does Biogen stock pay dividends?

No, Biogen (BIIB) stock does not pay dividends to its shareholders as of December 24, 2024.

When is the next Biogen dividend payment date?

Biogen (BIIB) stock does not pay dividends to its shareholders.

What is the beta indicator for Biogen?

Biogen (BIIB) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.